Supreme Court Won't Hear ANDA Venue Case
The U.S. Supreme Court on Monday rejected Mylan Pharmaceuticals Inc.'s challenge to the Federal Circuit's rule that generic-drug makers can face patent suits anywhere they may one day make sales....To view the full article, register now.
Already a subscriber? Click here to view full article